Cytogenetics and molecular cytogenetics in multiple myeloma

European Journal of Cancer

Volumn 42, Issue 11, 2006, Pages 1520-1529

  Liebisch, Peter ^a   Döhner, Hartmut ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Chromosome banding; Comparative genomic hybridization (CGH); Fluorescence in situ hybridization (FISH); Hyperdiploidy; IgH Translocation; Multiple myeloma; Paraproteinemias

Indexed keywords

ANEUPLOIDY; ARTICLE; CELL SELECTION; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 21; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FREQUENCY; GENE TRANSLOCATION; GENOMICS; HUMAN; METHODOLOGY; MOLECULAR GENETICS; MONOSOMY; MULTIPLE MYELOMA; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; TRISOMY;

CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; GENE EXPRESSION PROFILING; MULTIPLE MYELOMA; PROTEOMICS;

EID: 33746362589     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.12.028     Document Type: Article

References (104)

1. Dhodapkar M.V., and Sanderson R.D. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumour microenvironment. Leuk Lymphoma 34 (1999) 35-43
2. Jourdan M., Ferlin M., Legouffe E., et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100 (1998) 637-646
3. Debes-Marun C., Dewald G., Bryant S., et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17 (2003) 427-436
4. Dewald G.W., Kyle R.A., Hicks G.A., and Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma. plasma cell leukaemia, or amyloidosis. Blood 66 (1985) 380-390
5. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., and Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 71 (1988) 453-456
6. Weh H.J., Gutensohn K., Selbach J., et al. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 29A (1993) 1269-1273
7. Sawyer J. Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 (1995) 41-49
8. Lai J.L., Zandecki M., Mary J.Y., et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 85 (1995) 2490-2497
9. Zandecki M., Lai J.L., and Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94 (1996) 217-227
10. Calasanz M.J., Cigudosa J.C., Odero M.D., et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 98 (1997) 418-425
11. Tricot G., Sawyer J.R., Jagannath S., et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15 (1997) 2659-2666
12. Chesi M., Nardini E., Brents L.A., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 (1997) 260-264
13. Chesi M., Bergsagel P.L., Shonukan O.O., et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 91 (1998) 4457-4463
14. Sawyer J.R., Lukacs J.L., Munshi N., et al. Identification of new nonrandom translocations in multiple myeloma with multicolour spectral karyotyping. Blood 92 (1998) 4269-4278
15. Avet-Loiseau H., Brigaudeau C., Morineau N., et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 24 (1999) 9-15
16. Cigudosa J.C., Rao P.H., Calasanz M.J., et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 91 (1998) 3007-3010
17. Avet-Loiseau H., and Bataille R. Detection of nonrandom chromosomal changes in multiple myeloma by comparative genomic hybridization. Blood 92 (1998) 2997-2998
18. Aalto Y., Nordling S., Kivioja A.H., Karaharju E., Elomaa I., and Knuutila S. Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma. Genes Chromosomes Cancer 25 (1999) 104-107
19. Liebisch P., Viardot A., Bassermann N., et al. Value of Comparative Genomic Hybridization (CGH) and Fluorescence in situ Hybridization (FISH) for molecular diagnostics in multiple myeloma. Br J Haematol 122 (2003) 193-201
20. Gutierrez N.C., Garcia J.L., Hernandez J.M., et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 104 (2004) 2661-2666
21. Tchinda J., Volpert S., Kropff M., et al. Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization. Am J Clin Pathol 122 (2004) 875-882
22. Solinas-Toldo S., Lampel S., Stilgenbauer S., et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20 (1997) 399-407
23. Wendl C., Radlwimmer B., Wessendorf S., et al. Automated screening for genomic imbalances in multiple myeloma using microarray-based comparative genomic hybridization (M-CGH). Haematologica 90 (2005) 150 abstr; suppl 2
24. Tabernero D., San Miguel J.F., Garcia-Sanz M., et al. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149 (1996) 153-161
25. Avet-Loiseau H., Facon T., Grosbois B., et al. Intergroupe Francophone du Myelome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99 (2002) 2185-2191
26. Drach J., Schuster J., Nowotny H., et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55 (1995) 3854-3859
27. Drach J., Angerler J., Schuster J., et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86 (1995) 3915-3921
28. Fonseca R., Bailey R.J., Ahmann G.J., et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100 (2002) 1417-1424
29. Fonseca R., Oken M., and Greipp P. The t(4;14)(p16. 3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathies of undetermined significance. Blood 98 (2001) 1271-1272
30. Chng W.J., Van Wier S.A., Ahmann G.J., et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106 (2005) 2156-2161
31. Ahmann G.J., Jalal S.M., Juneau A.L., et al. A novel three-colour, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 101 (1998) 7-11
32. Avet-Loiseau H., Daviet A., Saunier S., and Bataille R. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 111 (2000) 1116-1117
33. Fonseca R., Oken M., Harrington D., et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia 15 (2001) 981-986
34. Elnenaei M.O., Hamoudi R.A., Swansbury J., et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 36 (2003) 99-106
35. Drach J., Ackermann J., Fritz E., et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92 (1998) 802-809
36. Avet-Loiseau H., Li J.Y., Godon C., et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 106 (1999) 717-719
37. Schultheis B., Krämer A., Willer A., Hegenbart U., Goldschmidt H., and Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 13 (1999) 2099-2103
38. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
39. Liebisch P., Wendl C., Wellmann A., et al. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 17 (2003) 2535-2537
40. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106 (2005) 2837-2840
41. Avet-Loiseau H., Facon T., Daviet A., et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process fo the oncogenesis of multiple myeloma Intergroupe Francophone du Myelome. Cancer Res 59 (1999) 4546-4550
42. Fonseca R., Harrington D., Oken M., et al. Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients. Blood 99 (2002) 3735-3741
43. Avet-Loiseau H., Li J.Y., Facon T., et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32). Cancer Res 58 (1998) 5640-5645
44. Rao P.H., Cigudosa J.C., Ning Y., et al. Multicolour spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92 (1998) 1743-1748
45. Sawyer J.R., Lukacs J.L., Thomas E.L., et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 112 (2001) 167-174
46. Sawyer J.R. Multicolour spectral karyotyping in multiple myeloma. Methods Mol Med 113 (2005) 49-58
47. Schwartz R.S. Jumping genes and the immunoglobulin V gene system. N Engl J Med 333 (1995) 42-44
48. Hallek M., Leif Bergsagel P., and Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91 (1998) 3-21
49. Kuehl W.M., and Bergsagel P.L. Multiple myeloma:increasing evidence for a multistep transformation process. Nat Rev Cancer 2 (2002) 175-187
50. Willis T.G., and Dyer M.J. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96 (2000) 808-822
51. Küppers R., and Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20 (2001) 5580-5594
52. Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., and Kuehl W.M. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 93 (1996) 13931-13936
53. Nishida K., Tamura A., Nakazawa N., et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukaemia as detected by in situ hybridization. Blood 90 (1997) 526-534
54. Bergsagel P.L., and Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene 20 (2001) 5611-5622
55. Bergsagel P., and Kuehl W. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194 (2003) 96-104
56. Kaufmann H., Ackermann J., Baldia C., et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 18 (2004) 1879-1882
57. Hideshima T., Bergsagel P.L., Kuehl W.M., and Anderson K.C. Advances in biology of multiple myeloma: clinical applications. Blood 104 (2004) 607-618
58. Greipp P.R., Trendle M.C., Leong T., et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 35 (1999) 83-89
59. Orfao A., Garcia-Sanz R., Lopez-Berges M.C., et al. A new method for the analysis of plasma cell DNA content in mutiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 17 (1994) 332-339
60. Latreille J., Barlogie B., Dosik G., Johnston D.A., Drewinko B., and Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood 55 (1980) 403-408
61. Smadja N.V., Bastard C., Brigaudeau C., Leroux D., and Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98 (2001) 2229-2238
62. Smadja N.V., Fruchart C., Isnard F., et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12 (1998) 960-969
63. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
64. Fonseca R., Debes-Marun C., Picken E., et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102 (2003) 2562-2567
65. Smadja N.V., Leroux D., Soulier J., et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid patients. Genes Chromosomes Cancer 38 (2003) 234-239
66. Liebisch P., Scheck D., Erné S.A., et al. Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma. Genes Chromosomes Cancer 42 (2005) 78-81
67. Zhan F., Tian E., Bumm K., Smith R., Barlogie B., and Shaughnessy Jr. J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101 (2003) 1128-1140
68. Tarte K., De Vos J., Thykjaer T., et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100 (2002) 1113-1122
69. Specht K., Haralambieva E., Bink K., et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104 (2004) 1120-1126
70. Smith L., Barlogie B., and Alexanian R. Biclonal and hypodiploid multiple myeloma. Am. J. Med 80 (1986) 841-843
71. Tricot G., Barlogie B., Jagannath S., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86 (1995) 4250-4256
72. Seong C., Delasalle K., Hayes K., et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 101 (1998) 189-194
73. Desikan R., Barlogie B., Sawyer J., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95 (2000) 4008-4010
74. Fassas A.B., Spencer T., Sawyer J., et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 118 (2002) 1041-1047
75. Shaughnessy J., Jacobson J., Sawyer J., et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 101 (2003) 3849-3856
76. Perez-Simon J.A., Garcia-Sanz R., Tabernero M.D., et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 91 (1998) 3366-3371
77. Zojer N., Königsberg R., Ackermann J., et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95 (2000) 1925-1930
78. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum ß-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
79. Fonseca R., Harrington D., Oken M., et al. Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study. Cancer Res 62 (2002) 715-720
80. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101 (2003) 1520-1529
81. Königsberg R., Ackermann J., Kaufmann H., et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 14 (2000) 1975-1979
82. Shaughnessy J., Tian E., Sawyer J., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96 (2000) 1505-1511
83. Liebisch P., Benner A., Tschajka K., et al. Gains on chromosome arm 9q represent a novel and independent marker of adverse prognosis in multiple myeloma patients receiving upfront high-dose chemotherapy and autologous stem cell transplantation. Haematologica 90 (2005) 88 abstr; suppl 2
84. Kröger N., Schilling G., Einsele H., et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103 (2004) 4056-4061
85. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
86. Dewald G.W., Therneau T., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106 (2005) 3553-3558
87. Chang H., Qi C., Yi Q.L., Reece D., and Stewart A.K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
88. Mazars G.R., Portier M., Zhang X.G., et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 7 (1992) 1015-1018
89. Corradini P., Inghirami G., Astolfi M., et al. Inactivation of tumour suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8 (1994) 758-767
90. Neri A., Baldini L., Trecca D., Cro L., Polli E., and Maiolo A.T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81 (1993) 128-135
91. Preudhomme C., Facon T., Zandecki M., et al. Rare occurrence of p53 gene mutations in multiple myeloma. Br J Haematol 81 (1992) 440-443
92. Ackermann J., Meidlinger P., Zojer N., Gisslinger H., Ludwig H., Huber H., and Drach J. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol 103 (1998) 1161-1163
93. Segeren C.M., Sonneveld P., van der Holt B., et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101 (2003) 2144-2151
94. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27(Kip1) and an aggressive clinical course in multiple myeloma. Haematology 10 Suppl 1 (2005) 117-126
95. Fonseca R., Witzig T.E., Gertz M.A., et al. Multiple myeloma and the translocation t(11;14)(q13;q32) - a report on 13 cases. Br J Haematol 101 (1998) 296-301
96. Zhan F., Hardin J., Kordsmeier B., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 (2002) 1745-1757
97. Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100 (2002) 1579-1583
98. Hoyer J.D., Hanson C.A., Fonseca R., Greipp P.R., Dewald G.W., and Kurtin P.J. The (11;14)(q13;q32) translocation in multiple myeloma A morphologic and immunohistochemical study. Am J Clin Pathol 113 (2000) 831-837
99. Robillard N., Avet-Loiseau H., Garand R., et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102 (2003) 1070-1071
100. Avet-Loiseau H., Garand R., Lode L., Harousseau J.-L., and Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101 (2003) 1570-1571
101. Soverini S., Cavo M., Cellini C., et al. Cyclin D1 overexpression is a favourable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 102 (2003) 1588-1594
102. Richelda R., Ronchetti D., Baldini L., et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90 (1997) 4062-4070
103. Keats J.J., Reiman T., Maxwell C.A., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101 (2003) 1520-1529
104. Santra M., Zhan F., Tian E., Barlogie B., and Shaughnessy Jr. J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101 (2003) 2374-2376